Physician profile
Tene Redman
NPI 1275021297
$1,224.74
in general payments reported to CMS, 2019-2025
14 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $132 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $241.61 | 2025 | |
| Abbvie INC. | $129.21 | 2024-2025 | |
| Tris Pharma INC | $110.71 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Axsome Therapeutics, INC. | $109.54 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $98.84 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.17 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $81.86 | 2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $79.70 | 2024-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $66.06 | 2025 | Trintellix |
| Alkermes, INC. | $64.33 | 2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $58.14 | 2025 | Fanapt |
| Almatica Pharma LLC | $43.30 | 2025 | Loreev Xr |
| Lundbeck LLC | $31.74 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $19.53 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tene Redman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.